Analyst firms · Barclays · TVRD
Barclays TVRD price target and rating history
Tvardi Therapeutics Inc. (TVRD) · Health Care
Barclays rates Tvardi Therapeutics Inc. (TVRD) Underweight with a $3 price target, as of its latest action on Apr 20, 2026. It has published 3 rating actions on TVRD since October 2025, including 0 upgrades and 2 downgrades. Across 5 firms with a TVRD price target in the last 12 months, the median target is $9. Barclays's $3 is 67% below that.
- Current rating
- Underweight
- Price target
- $3
- Median target, all firms
- $9
- Actions on TVRD
- 3
Barclays price target on TVRD
Every Barclays rating on TVRD
- Apr 20, 2026
- Oct 14, 2025
- Oct 13, 2025
How other firms rate TVRD
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Chardan Capital Markets | Buy | $8 | Oct 20, 2026 |
| Piper Sandler | Overweight | $13 | Jul 8, 2026 |
| Raymond James | Outperform | $10 | Jul 8, 2026 |
| H.C. Wainwright | Buy | $9 | Jun 8, 2026 |
| Barclays | Underweight | $3 | Apr 20, 2026 |
Questions about Barclays and TVRD
- What is Barclays's price target for TVRD?
- Barclays's latest stated price target for Tvardi Therapeutics Inc. (TVRD) is $3, from its action on Apr 20, 2026.
- What is Barclays's rating on TVRD?
- Barclays rates TVRD Underweight, a bearish rating, as of Apr 20, 2026.
- When did Barclays last change its view on TVRD?
- On Apr 20, 2026, Barclays downgrades to Underweight from Equal Weight, price target $3.
- How does Barclays's TVRD target compare with other analysts?
- Across 5 firms with a TVRD price target in the last 12 months, the median target is $9. Barclays's $3 is 67% below that.
More TVRD rating histories
All Barclays ratingsTVRD news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.